Literature DB >> 3002577

Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). I. Intraductal carcinoma (DCIS).

E R Fisher, R Sass, B Fisher, L Wickerham, S M Paik.   

Abstract

Seventy-eight examples of intraductal carcinoma (DCIS) were identified after pathologic review of 2072 specimens obtained from National Surgical Adjuvant Breast Project protocol 6. This randomized clinical trial compares the therapeutic merit of total mastectomy (TM) with lumpectomy (L), with (LX) and without (LO) postoperative irradiation. All patients were subjected to axillary lymph node dissection. Seven (14%) of the 51 patients with DCIS treated by L exhibited breast recurrence within or close to the site of the initial lesion 4 to 53 months (average, 16 months) after L. Only 2 (7%) of these events occurred in the 29 women treated by LX, as opposed to 23% in the LO group. No pathologic features were noticed that might have been considered predictive of local breast recurrence. The three DCIS recurrences and the four invasive forms noted are considered to represent overlooked or incompletely excised foci of cancer because of the multifocality (not multicentricity) of some breast cancers. The possibility that DCIS may represent a marker of risk for the development of cancer rather than a precursor lesion per se is suggested. Despite apparent difficulties in the pathologic diagnosis of DCIS as well as uncertainty concerning its natural history, no evidence was found to indicate that it represents a more ominous disease than invasive cancer. Indeed, treatment failure occurred in only one patient treated by LX and a similar number subjected to TM (4% versus 2%). Although these observations are short term (average follow-up, 39 months), estimates of the probability of local recurrence or survival suggest that they will not be significantly altered after longer periods of surveillance. Thus, there are no compelling reasons why DCIS may not be treated in a cosmetically acceptable manner by LX. A randomized clinical trial addressing this issue is now in progress.

Entities:  

Mesh:

Year:  1986        PMID: 3002577     DOI: 10.1002/1097-0142(19860115)57:2<197::aid-cncr2820570203>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  29 in total

1.  Telomere length variation in normal epithelial cells adjacent to tumor: potential biomarker for breast cancer local recurrence.

Authors:  Xin Zhou; Alan K Meeker; Kepher H Makambi; Ourania Kosti; Bhaskar V S Kallakury; Mary K Sidawy; Christopher A Loffredo; Yun-Ling Zheng
Journal:  Carcinogenesis       Date:  2011-11-09       Impact factor: 4.944

2.  A Case of Ductal Carcinoma In Situ (DCIS:noncomedo type)Detected by Ultrasonography: Demonstration of Occult Multiple Foci.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

3.  Local Recurrence after Conservative Surgery for Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

4.  Pathologic Assessment of Surgical Margins on Frozen and Permanent Sections in Breast Conserving Surgery.

Authors: 
Journal:  Breast Cancer       Date:  1995-04-30       Impact factor: 4.239

Review 5.  Management of ductal carcinoma in situ of the breast.

Authors:  N J Carty; C Carter; G T Royle; C D Johnson
Journal:  Ann R Coll Surg Engl       Date:  1995-05       Impact factor: 1.891

6.  Ductal carcinoma in situ detected by screening.

Authors: 
Journal:  BMJ       Date:  1990-09-01

7.  Radiotherapy for ductal carcinoma in situ detected by screening.

Authors:  C R Hamilton; R B Buchanan
Journal:  BMJ       Date:  1990-07-28

8.  Natural history of in situ breast cancer in a defined population.

Authors:  W J Temple; M Jenkins; F Alexander; W S Hwang; L H Marx; A W Lees; H T Williams; M G Pambrun
Journal:  Ann Surg       Date:  1989-11       Impact factor: 12.969

Review 9.  Management of in situ and minimally invasive breast carcinoma.

Authors:  E R Frykberg; K I Bland
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

10.  Treatment of primary breast cancer without mastectomy. The Los Angeles community experience and review of the literature.

Authors: 
Journal:  Ann Surg       Date:  1986-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.